THE BREAST CANCER RESEARCH FOUNDATION expanded its research program with a new collaborative breast cancer funding model, the BCRF Investigator-Initiated Drug Research Program. The received a three-year, $15 million grant from Pfizer to support this effort, as well as access to Pfizer’s portfolio of products. “It will encourage more creative, academic-driven research and give more...
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).Â
